5 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: ... Full Year and Q4 2024 results clinical trials appendix. PDF 2,467KB Explore our clinical …

5 days ago · On Thursday 6 February 2025 we announced our Full Year and Q4 2024 results. An accompanying webcast for investors and analysts took place at 11:00 UK time. ... This website …

5 days ago · Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025. 2 ... AstraZeneca credit ratings: Moody’s: short-term rating P-1, long -term …

4 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% …

4 days ago · AstraZeneca’s Full Year and Q4 2024 results. Business Wire . Thu, Feb 6, 2025, 7:00 AM 9 min read. In This Article: AZN . AZNCF . Strong momentum in FY 2024 with Total …

6 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% …

4 days ago · Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read …

Financial performance for FY 2024 (Growth numbers at constant exchange rates) ‒ Total Revenue up 21% to $54,073m, driven by a 19% increase in Product Sales, continued growth …

4 days ago · AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total revenue up 21% and core EPS up 19%, indicating robust company momentum. The …

5 days ago · AstraZeneca continues to fully cooperate with the Chinese authorities. In December 2024 AstraZeneca announced the appointment of Iskra Reic as Executive Vice President, …